Prognostic evaluation of immunohistochemical profiles in diffuse large B-cell lymphoma: a Chinese study. (Q51720793)

10 April 2018

title

Prognostic evaluation of immunohistochemical profiles in diffuse large B-cell lymphoma: a Chinese study. (English)

1 reference

10 April 2018

diffuse large B-cell lymphoma

1 reference

1 reference

1 reference

Zi Chen

1

1 reference

10 April 2018

Zunguo Du

2

1 reference

10 April 2018

Jieqing Chen

3

1 reference

10 April 2018

Zhongqing Chen

4

1 reference

10 April 2018

Yun Bao

5

1 reference

10 April 2018

Feng Tang

6

1 reference

10 April 2018

publication date

18 February 2010

1 reference

10 April 2018

published in

Medical Oncology

1 reference

10 April 2018

volume

28

1 reference

10 April 2018

issue

1

1 reference

10 April 2018

page(s)

241-248

1 reference

10 April 2018

Molecular pathogenesis of diffuse large B-cell lymphoma

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9433-3

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9433-3

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9433-3

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9433-3

Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9433-3

Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9433-3

Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9433-3

Conditional survival of patients with diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9433-3

Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9433-3

International prognostic index-based outcomes for diffuse large B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9433-3

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9433-3

Variability in immunophenotype in diffuse large B-cell lymphoma and its clinical relevance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9433-3

Biomarkers of potential prognostic significance in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9433-3

Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9433-3

Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9433-3

De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9433-3

Prognostic evaluation of nodal diffuse large B cell lymphoma by immunohistochemical profiles with emphasis on CD138 expression as a poor prognostic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9433-3

Absence of cyclin-D2 and Bcl-2 expression within the germinal centre type of diffuse large B-cell lymphoma identifies a very good prognostic subgroup of patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9433-3

RETRACTED: Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9433-3

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

21 January 2018

1 reference

12 December 2020

Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5- with CD10+ groups may constitute clinically relevant subtypes

1 reference

12 December 2020

Genetic analysis of de novo CD5+ diffuse large B-cell lymphomas suggests an origin from a somatically mutated CD5+ progenitor B cell

1 reference

12 December 2020

A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project

1 reference

12 December 2020

Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores.

1 reference

12 December 2020

Usefulness of immunohistochemistry in identification of prognostically important subgroups (GCB and ABC) in a heterogeneous group of diffuse large B-cell lymphomas--a review article.

1 reference

12 December 2020

CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas

1 reference

12 December 2020

10.1007/S12032-010-9433-3

Identifiers

DOI

1 reference

10 April 2018

1 reference

10 April 2018